Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gynecologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1

Conditions

Neoplasm Metastasis 3Breast Neoplasms 3Ovarian Neoplasms 2Mesothelioma 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

Paclitaxel 50Capecitabine 50Trastuzumab 38Fulvestrant 31pembrolizumab 27Cyclophosphamide 27Carboplatin 27Gemcitabine 23Letrozole 21palbociclib 19Docetaxel 19Lapatinib 18Bevacizumab 18exemestane 17eribulin 15Everolimus 14abemaciclib 13Vinorelbine 13Nivolumab 13Magnetic Resonance Spectroscopy 12Cisplatin 12Anastrozole 12trastuzumab deruxtecan 11Zoledronic Acid 11Doxorubicin 11Albumin-Bound Paclitaxel 11olaparib 10Tamoxifen 10Specimen Handling 10Radiotherapy 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × rebastinib × Breast × Clear all
NCT03601897 2024-12-27

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
177 enrolled 25 charts
BreastGynecologicSarcoma

Breast Neoplasms, Carcinosarcoma, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT03717415 2024-12-27

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
70 enrolled 24 charts
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms

NCT02824575 2022-04-04

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Montefiore Medical Center

Phase 1 Terminated
28 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡